| |  | | Taiwan BIO Weekly | | Ainos Licenses VELDONA to BioPhoenix for Development in Two Indications | | 13 October, 2026 | | San Fu Chemical’s (4755) subsidiary, BioPhoenix Co., held a licensing agreement signing ceremony today with U.S.-based Nasdaq-listed Ainos, Inc. Under the agreement, BioPhoenix will obtain worldwide rights to develop, manufacture, and commercialize two indications for VELDONA®, Ainos’ low-dose oral interferon drug: Sjögren’s syndrome (also known as sicca syndrome) and thrombocytopenia. | | | | | | Foresee Pharma’s CAMCEVI® 42 mg Approved in China for Advanced Prostate Cancer | | 12 October, 2026 | | Foresee Pharmaceuticals (TPEx: 6576), today announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), that China's National Medical Products Administration (NMPA) has approved the Marketing Authorization Application (MAA) for CAMCEVI® 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, for the treatment of adult patients with advanced prostate cancer. | | | | | | TFBS Bioscience Celebrates 10th Anniversary, Expanding Gene Therapy and CDMO Partnerships in Japan and Taiwan | | 14 October, 2026 | | TFBS Bioscience (6939) celebrates its 10th anniversary, announcing four major partnerships and development milestones today (October 14). Its partners include Japan’s ONODERA GT Pharma and TOKIWA Bio, Taiwan’s Medigen Vaccine Biologics, and Singapore-based Amamus Life Technology. Through these cross-border collaborations, TFBS aims to expand its presence in the Japanese market, strengthen its viral vector manufacturing and testing capabilities, and reinforce Taiwan’s biotechnology supply chain. | | | | | | Synmosa Secures Licensing Deal for Japanese Sleeping Medication | | 15 October, 2026 | | Synmosa Biopharma(4114) announced on October 14 that it had signed an exclusive licensing, supply, and commercialization agreement with Nxera Pharma Japan, a subsidiary of Japan-based Nxera Pharma, for QUVIVIQ (daridorexant), a treatment for insomnia. Under the agreement, Synmosa will obtain the rights to market the drug in eight Asia-Pacific markets: Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia, and New Zealand. | | | | | | PharmaEssentia Secures China Approval for Ropeg to Treat ET, Eyes National Reimbursement Listing | | 16 October, 2026 | | PharmaEssentia’s (6446) innovative, long-acting interferon therapy, ropeginterferon alfa-2b (Ropeg, also known as P1101), has received approval from China’s National Medical Products Administration (NMPA) for an additional indication: the treatment of adults with essential thrombocythemia (ET) who have had an inadequate response to prior hydroxyurea (HU) therapy. This approval marks another milestone in Ropeg’s global expansion into the ET market and further strengthens its commercialization prospects in China’s myeloproliferative neoplasm (MPN) market. | | | | | | AP Biosciences Licensing Momentum Grows as Two Pharma Companies Show Interest in Its Novel HER2 Drug | | 15 October, 2026 | | AP Biosciences (6945) announced on October 15 that its next-generation HER2-targeted drug attracted interest from two leading global oncology companies during its participation in BioJapan 2026. The company has been invited to further discuss potential collaborations during next year’s J.P. Morgan Healthcare Conference. | | | | | | MetaTech AP Unveils 2027 Growth Strategy, Partners with Zheng Yang Biomedical to Build a Regenerative Medicine Supply Chain | | 15 October, 2026 | | MetaTech AP Inc. (TPEx: 3224) held its investor conference today, presenting its 2026 operating performance and strategic outlook for 2027. Revenue for the first nine months of 2026 reached NT$1.391 billion, representing 21% year-over-year growth. With electronics and biomedicine serving as its two growth engines, MetaTech AP is actively expanding its presence in the global AI supply chain and regenerative medicine market. | | | | | | Enimmune Expands Its Vaccine Presence in Malaysia | | 16 October, 2026 | | Enimmune Corporation(6564) announced a strategic partnership with Malaysia’s Duopharma Biotech to collaborate on the distribution and sales of vaccines in Malaysia. The partnership aims to expand access to both public health and private-pay vaccine markets while strengthening the company’s presence across Southeast Asia. | | | | | | Medeon Reports Breakthrough in U.S. Market for Minimally Invasive Medical Devices | | 15 October, 2026 | | Medeon Biodesign (6499) announced on October 15 that its innovative minimally invasive medical device, Urocross, for the treatment of benign prostatic hyperplasia (BPH) has successfully completed its first commercial clinical procedure at Westlake Medical Center in Austin, Texas. The milestone marks the product’s official entry into the commercialization phase and represents a significant step forward in the company’s expansion into the U.S. market. | | | | | | | | | | | |
